{
    "clinical_study": {
        "@rank": "21583", 
        "arm_group": {
            "arm_group_label": "Stem cells implantation", 
            "arm_group_type": "Experimental", 
            "description": "Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device."
        }, 
        "brief_summary": {
            "textblock": "The aim of the  study is to investigate safety and efficacy of intramyocardial implantation\n      of allogeneic mesenchymal stem cells in patients with end-stage ischemic cardiomyopathy\n      undergoing left ventricular assist device implantation."
        }, 
        "brief_title": "Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Heart Failure", 
            "Ischemic Cardiomyopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "End-stage ischemic cardiomyopathy (ICM) with non-graftable coronary arteries is a common and\n      debilitating problem. The ultimate therapeutic goal in such cases is cardiac transplantation\n      which is restricted by donor availability. Alternatively, left ventricular assist devices\n      (LVAD) are increasingly used as bridge to transplantation or more recently as destination\n      therapy in non-transplant candidates. Widely used second- and third-generation\n      continuous-flow LVAD offer symptomatic relief and prolong life. However, LV unloading rarely\n      improves native heart function in ischemic hearts. We aim to increase myocardial viability\n      and improve native cardiac function in  patients with end-stage ICM by injecting allogeneic\n      bone marrow stem cells at the time of LVAD implantation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 to 75 years\n\n          -  End-stage heart failure due to ischemic cardiomyopathy that requires mechanical\n             support according to current indications\n\n          -  Ability to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Not willing to provide informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01759212", 
            "org_study_id": "AHEPA_CTL_02"
        }, 
        "intervention": {
            "arm_group_label": "Stem cells implantation", 
            "intervention_name": "Allogeneic stem cells implantation", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stem cell implantation", 
            "coronary artery disease", 
            "left ventricular assist device"
        ], 
        "lastchanged_date": "November 27, 2013", 
        "location": {
            "contact": {
                "email": "antonits@auth.gr", 
                "last_name": "Polychronis Antonitsis, MD, DSc", 
                "phone": "+30 2310 994871"
            }, 
            "facility": {
                "address": {
                    "city": "Thessaloniki", 
                    "country": "Greece", 
                    "zip": "546 36"
                }, 
                "name": "AHEPA University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Kyriakos Anastasiadis, MD, DSc, FETCS", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Polychronis Antonitsis, MD, DSc", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Efficacy of Intramyocardial Implantation of Allogeneic Mesenchymal Stem Cells in Patients With End-stage Heart Failure Undergoing Left Ventricular Assist Device Implantation", 
        "overall_contact": {
            "email": "antonits@auth.gr", 
            "last_name": "Polychronis Antonitsis, MD, DSc", 
            "phone": "+30 2310 994871"
        }, 
        "overall_official": {
            "affiliation": "AHEPA University Hospital", 
            "last_name": "Kyriakos Anastasiadis, MD, DSc, FETCS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Greece: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Improvement in myocardial perfusion/viability assessed with SPECT segmental analysis", 
            "measure": "Improvement in myocardial perfusion/viability", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "reference": [
            {
                "PMID": "21852003", 
                "citation": "Anastasiadis K, Antonitsis P, Doumas A, Koliakos G, Argiriadou H, Vaitsopoulou C, Tossios P, Papakonstantinou C, Westaby S. Stem cells transplantation combined with long-term mechanical circulatory support enhances myocardial viability in end-stage ischemic cardiomyopathy. Int J Cardiol. 2012 Mar 22;155(3):e51-3. doi: 10.1016/j.ijcard.2011.07.062. Epub 2011 Aug 17."
            }, 
            {
                "PMID": "21247486", 
                "citation": "Anastasiadis K, Antonitsis P, Argiriadou H, Koliakos G, Doumas A, Khayat A, Papakonstantinou C, Westaby S. Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion. J Transl Med. 2011 Jan 19;9:12. doi: 10.1186/1479-5876-9-12. Review."
            }, 
            {
                "PMID": "22378852", 
                "citation": "Ibrahim M, Rao C, Athanasiou T, Yacoub MH, Terracciano CM. Mechanical unloading and cell therapy have a synergistic role in the recovery and regeneration of the failing heart. Eur J Cardiothorac Surg. 2012 Aug;42(2):312-8. doi: 10.1093/ejcts/ezs067. Epub 2012 Feb 29. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01759212"
        }, 
        "responsible_party": {
            "investigator_affiliation": "AHEPA University Hospital", 
            "investigator_full_name": "Kyriakos Anastasiadis", 
            "investigator_title": "Associate Professor Kyriakos Anastasiadis", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "all-cause morbidity", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "Change in left ventricular function after combined mechanical and cellular therapy", 
                "measure": "left ventricular function", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "all-cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }
        ], 
        "source": "AHEPA University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AHEPA University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}